Belite Bio clinical trials we track

Check company identity source

Phase 3 2 trials

Phase 2 / 3 1 trial

TrialDrugs studiedStatusPrimary completion
A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt DiseaseNCT06388083TinlarebantActive not recruiting2028-02Estimated

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2027-02-12DayTinlarebantBelite Bio, Inc · BLTECompany-disclosed PDUFA goal dateAnnounced review targetStargardt disease type 1Open original source
Read source excerpt

U.S. Food and Drug Administration accepted the New Drug Application with Priority Review for tinlarebant for the treatment of Stargardt disease type 1; Prescription Drug User Fee Act target action date of February 12, 2027

First seen: 26 Sep 2026 · Evidence last checked: 26 Sep 2026

2027-02-12DayTinlarebantBelite Bio, Inc · BLTECompany-disclosed PDUFA goal dateAnnounced review targetStargardt disease type 1 (STGD1)Open original source
Read source excerpt

New Drug Application (NDA) for tinlarebant in Stargardt disease type 1 (STGD1) granted priority review by the U.S. Food and Drug Administration (FDA) in August 2026 with Prescription Drug User Fee Act (PDUFA) target action date of February 12, 2027

First seen: 13 Nov 2026 · Evidence last checked: 13 Nov 2026

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters